TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Exhaled Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of acute grade II/IV GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SKAMP-Combined Scores at Hour 4 Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emerged Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral Immune Response (HI Antibodies Titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pneumococcal Vaccine Response (Anti-pneumococcal Antibody Concentrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression of Myosin VI and oestrogen receptor targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantification of Myosin VI protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Localisation of Myosin VI on the tumour genome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proportion of ventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Normal/Abnormal Bone Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visualization of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of long-term benzodiazepine users that managed to quit or significantly reduce their use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Objectively Confirmed VTE Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with mean % Pain Intensity Difference >= 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good obstetric outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in Total Chloride Transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Normalization of Chloride Transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study drug dosage in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Duration of Superior Hyolaryngeal Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Duration of Hyoid Maximum Anterior Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-Year Event-Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Participants With a Complete Response (CR)
Endpoint domain: Mortality/survival
Primary endpoint: change of frequency of hypoglycemia onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of glycated albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-reported breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Time Management Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete cure of mucosal defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in heavy drinking/drug using days at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in depressive symptoms at 18-20 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in depressive symptoms at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio (HR)
Endpoint domain: Mortality/survival
Primary endpoint: Adherence With Cancer Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Cancer Diagnosis To First Oncology Appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dead space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Termination of Ventricular Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge of Reproductive Health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cases of access to the endometrial cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the average daily frequency of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Cured at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Procedural success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Degree of parental concern
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Investigator Global Assessment of Atopic Dermatitis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Completion of a questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-stigma related to suicide attempt
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lifetime HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV Self-Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV Self-Test Results Disclosure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants biopsied
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Hospital Anxiety and Depression Scale (HADS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in health related quality of life as assessed by the Eating Disorder Quality of Life Scale (EDQLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment-emergent hepatic injury or dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Treatment-emergent renal failure or dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Death from hepatocellular carcinoma (HCC)
Endpoint domain: Mortality/survival
Primary endpoint: Doubling of total motile sperm count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Arrest of atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of nasal High-Flow Nasal Cannula (HFNC) Oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cerebrovascular properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probing pocket depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone level stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4 T-cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Depression as Measured by Beck Depression Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived Stress as Measured by Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of ovulation as measured by day-21 serum progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients who have lost at least 5% of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement/deterioration of clinical symptoms: hyper androgenic features, obesity and menstrual disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Medication Adherence (Visual Analog Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Medication Adherence (Hair Sample Assay)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Aflibercept injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite of plasma pharmacokinetic parameters of Tivantinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total RBC glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of microvascular anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients remaining free of need for mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in DAS28 (Disease Activity Score 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptability of the app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Virological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lesion change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical and clinical disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving Disease Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postprandial capillary glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of symptoms of polymorphic light eruption
Endpoint domain: Adverse events/effects
Primary endpoint: 1 year postoperative anastomotic recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-16 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of oral clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facility delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Urinary and Fecal Excretion of LY2157299 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cow's milk allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial beta-cell function (insulin secretion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial hepatic insulin sensitivity (suppression of endogenous glucose production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: per operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Volume of distribution of vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of nipple-areola complex (NAC) or skin flap necrosis requiring specific treatment/surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of infection requiring surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Upper airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in monocyte cellular energetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of days on sick-leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time until sustainable return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Duration of Urticaria Until Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pulmonary arterial pressure after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: achievement of low risk
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Appearance of endometrial cancer
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of atypical endometrial lesions
Endpoint domain: Mortality/survival
Primary endpoint: Amount of patients discharged from the hospital until 10 am at the first postoperative day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Analgesic consumption postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time up and go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unique signal measured in Hertz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Young Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-RS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative static and dynamic numeric rating scale (NRS) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Event-Free Survival (EFS) at Week 240
Endpoint domain: Mortality/survival
Primary endpoint: Pain Level Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Function Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Favourable Modified Rankin Scale (mRS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative number of new gadolinium-enhanced T1 weighted lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Adverse events and infections occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of anti-ACZ885 antibodies in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower ureteric stone expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Androgen deprivation therapy free survival
Endpoint domain: Mortality/survival
Primary endpoint: Intraocular pressure-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Confirmed Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Insulinemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with American College of Rheumatology (ACR) 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Disease Activity Score (DAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in average neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the range of movement (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in quadriceps muscle circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscle strength of quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the assessment of radiological joint deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Independence Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neutrophil Delivery to the Oral Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Cigarettes Smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial pathologic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survivorship of the INFINITY™ Total Ankle System
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection and quantitation of circulating osteosarcoma cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gingival crevicular fluid (GCF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Primary Blood Stream Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Clinical (Culture-negative) Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Amount of information received on aspects of fertility and infertility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Response Rate (ORR) of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with successful selective cannulation of coronary ostia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mammary Nucleus Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in brachial Flow Mediated Dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of unprotected sex acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adverse events including infusion-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Body composition assessment using deuterium dilution method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes